Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $937,537
Sep 15, 2025 – Aug 31, 2027
Solicitation PA24-245 (2024) · Topic 400
An improved low-endotoxin Clean Genome E. coli strain for production of biological products
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,648,252
Sep 1, 2024 – Aug 31, 2027
Solicitation PA23-230 (2023) · Topic 400
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,906,252
Jul 13, 2020 – Jun 30, 2023
Solicitation PA19-272 (2019) · Topic NIAID
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,649,139
Jul 1, 2019 – Jun 30, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $3,000,000
Mar 20, 2019 – Feb 28, 2022
Solicitation PA18-574 (2018) · Topic NIAID
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $156,171
Jan 1, 2019 – Jun 30, 2019
Solicitation PA18-574 (2018) · Topic NIAID
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E. coli strains
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,584,682
Aug 1, 2017 – Jul 31, 2019
Solicitation PA15-269 (2015) · Topic NIAID
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $154,222
Dec 15, 2016 – May 31, 2017
Solicitation PA15-269 (2015) · Topic NIAID
Characterization of a low mutation rate E coli in extended fermentation
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $2,418,530
Jun 1, 2016 – May 31, 2019
Solicitation PA14-071 (2014) · Topic 200
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,461,610
May 20, 2014 – Apr 30, 2017
Solicitation PA13-234 (2014) · Topic NIAID
Characterization of a low mutation rate E. coli in extended fermentation
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $282,618
Solicitation PA12-088 (2013) · Topic NIGMS · Research partner: Stub
A protease-deficient, low mutation rate E. coli for biotherapeutics production
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $1,624,414
Solicitation PA12-088 (2013) · Topic NIGMS · Research partner: Stub
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $140,925
Solicitation PA11-096 (2012) · Topic NIAID · Research partner: Stub
A protease-deficient, low mutation rate E. coli for biotherapeutics production
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $155,032
Solicitation PA12-088 (2012) · Topic NIGMS · Research partner: Stub
Innate Immune Protection by Clean Genome E. coli
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2011 · $1,748,517
Solicitation PA09-080 (2011) · Topic NIAID · Research partner: Stub
Uniform length DNA for paired end nextgen sequencing via in vitro packaging
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $127,387
Solicitation PHS2010-2 (2010) · Topic NIAID
Innate Immune Protection by Clean Genome E. coli
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $139,981
Solicitation PHS2010-2 (2010) · Topic NIAID
Improved bacterial strains for therapeutic DNA and protein production
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2009 · $1,825,980
Solicitation PHS2009-2 (2009)
Engineered revision of the E. coli Nissle 1917 Genome
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $141,037
Solicitation PHS2007-2 (2008)
Improved bacterial strains for therapeutic DNA production
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $139,203
Solicitation year 2007
Clean-Genome vaccines against biodefense agents
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $1,000,000
Solicitation PHS2006-2 (2006)
Engineered Revision of E. coli for Production of DNA, Proteins and Metabolites
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2005 · $1,337,280
Solicitation PHS2005-2 (2005)
Engineered Revision of the E. coli Genome for Production
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $100,000
Solicitation PHS2004-2 (2004)
Engineering E. coli for periplasmic protein production
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $109,429
Solicitation PHS2004-2 (2004)
Engineering E. coli for periplasmic protein production
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $1,041,260
Solicitation PHS2004-2 (2004)
